Tarsus Pharmaceuticals, Inc. Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc.

TARS

Kedudukan dalam Saham #4678
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Harga Saham
$68.99
Modal Pasaran
$3.23B
Perubahan (1 hari)
1.34%
Perubahan (1 tahun)
-5.41%
Negara
US
Perdagangan Tarsus Pharmaceuticals, Inc. (TARS)

Kategori

Healthcare
EPS untuk Tarsus Pharmaceuticals, Inc. (TARS)
EPS setakat June 2026 TTM: $-1.09
Menurut laporan kewangan terkini dan harga saham Tarsus Pharmaceuticals, Inc., EPS semasa syarikat (TTM) adalah $-1.09. Pada akhir tahun 2023, syarikat mempunyai EPS sebanyak $-4.62 peningkatan berbanding EPS tahun 2022 iaitu $-2.52.
Sejarah EPS untuk Tarsus Pharmaceuticals, Inc. dari 2018 hingga 2026
EPS pada akhir setiap tahun
Tahun EPS Ubah
2026 (TTM) $-1.09 -64.50%
2024 $-3.07 -33.55%
2023 $-4.62 83.33%
2022 $-2.52 276.12%
2021 $-0.67 -49.24%
2020 $-1.32 450.00%
2019 $-0.24 -22.58%
2018 $-0.31 0.00%
EPS untuk syarikat atau pesaing yang serupa
Syarikat EPS Perbezaan EPS Negara
$17.32 -1,688.99%
US
$-7.98 632.11%
US
$-5.29 385.32%
AU
- -
CH
$27.74 -2,644.95%
NL